Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185295 | 1.00 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL5186326 | 1.00 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL6180731 | 1.00 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL6143168 | 0.94 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL6143163 | 0.94 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL5187064 | 0.92 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL5187060 | 0.92 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL6180558 | 0.92 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL5185457 | 0.92 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL5187054 | 0.90 | KCNH2 (0.59) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232834-B2 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL SA (FR) | 2007-06-19 | — | — | US | claimed |
| EP-1542988-B1 | PIPERIDINE QUINOLYL PROPYL DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES AND COMPOSITIONS CONTAINING SAME | NOVEXEL (FR) | 2006-04-12 | — | — | EP | claimed |
| US-20040087619-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL SA (FR) | 2004-05-06 | — | — | US | claimed |
| US-7232834-B2 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL SA (FR) | 2007-06-19 | — | — | US | disclosed |
| EP-1542988-A1 | PIPERIDINE QUINOLYL PROPYL DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2005-06-22 | — | — | EP | disclosed |
| US-20040087619-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL SA (FR) | 2004-05-06 | — | — | US | disclosed |
| WO-2004024712-A1 | PIPERIDINE QUINOLYL PROPYL DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087619-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | FARSB, MRPL21, QTRT1 | KCNH2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.